The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of March. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

(Click on drug name to go to MPR monograph.)  D IND ITX CI W/P ADR HS MFR
BETASERON (interferon beta-1b) X X X X X X
CALDOLOR (ibuprofen) X X X X X
DALIRESP (roflumilast) X
DEXILANT (dexlansoprazole) X
EXTAVIA (interferon beta-1b) X X
HARVONI (ledipasvir/sofosbuvir) X X X X X X
KETEK (telithromycin) X X X X
OXTELLAR XR (oxcarbazepine) X X
PREVACID SOLUTAB (lansoprazole) X
TYBOST (cobicistat) X X
VIEKIRA PAK (ombitasvir/paritaprevir/ritonavir with dasabuvir) X X X X
XOLAIR (omalizumab) X
Review more drug monograph updates